Vertex Wins FDA Nod to Give Casgevy CRISPR Therapy to Toddlers

LONDON, Saturday, July 4, 2026 — The U.S. Food and Drug Administration approved Vertex Pharmaceuticals' CRISPR gene therapy Casgevy for children as young as two on July 1, adding roughly 5,500 eligible U.S. patients and making it the first genetic medicine cleared for toddlers with sickle cell disease or beta thalassemia. Vertex said the label now covers anyone aged two and above with either condition. The decision extends the reach of the world's first approved CRISPR medicine into pediatric care. It also raises the commercial stakes for a therapy whose uptake has lagged its scientific milestones.

Key Takeaways

• Casgevy, co-developed by Vertex and CRISPR Therapeutics, is now the first and only gene therapy approved for children as young as two for both sickle cell disease and transfusion-dependent beta thalassemia.
• The expansion adds approximately 5,500 eligible U.S. children, accessible through more than 75 authorized treatment centers.
• Casgevy generated $42.9 million in first-quarter 2026 sales and $116 million across full-year 2025, still short of blockbuster scale.
• The FDA cleared the label just 53 days after filing under its Commissioner's National Priority Voucher — the eighth approval under the scheme.

Context and Analysis

Casgevy's original December 2023 clearance marked the first FDA approval of a CRISPR/Cas9 medicine in human history. The therapy edits a patient's own blood stem cells at the BCL11A gene to boost fetal hemoglobin, which keeps red blood cells from sickling. The pediatric approval rests on Phase 3 data in children aged five to under 12, with the FDA extending the indication down to age two by extrapolation rather than direct trial enrollment in the youngest cohort. All eight evaluable sickle cell patients were free of severe vaso-occlusive crises for at least 12 consecutive months, and eight of nine evaluable thalassemia patients stopped needing transfusions.

Speed was the story on the regulatory side. The FDA granted the decision 53 days after filing, the eighth approval under its Commissioner's National Priority Voucher program, against traditional review times of 10 to 12 months.

Related: Genetics Innovation Hits an Inflection Point as Editing Moves From Lab to Market

Competitive Landscape

Casgevy stands alone as an approved CRISPR product, but rivals are closing on the same biology. Beam Therapeutics has dosed dozens of patients with BEAM-101, a base-editing approach that also reactivates fetal hemoglobin, and intends to file for commercialization by the end of 2026. Base editing avoids double-strand DNA breaks, a potential safety advantage. Meanwhile, both Vertex and CRISPR are chasing less invasive delivery. Early research programs are reported to be investigating approaches such as less intensive conditioning regimens that could reactivate fetal hemoglobin without myeloablative chemotherapy, according to company disclosures.

Related: Best Genomics Conferences 2026 in London UK, Europe, US/Canada and UAE

Additional coverage: Genetics market size surges amid sequencing boom and therapy wins

Why It Matters

For Enterprise Buyers

Payers and health systems now face a larger pediatric population for a one-time therapy priced at $2.2 million. The federal Cell and Gene Therapy Access Model, a CMS-led outcomes-based framework, negotiates reimbursement with Vertex on behalf of state Medicaid programs, with rebates if outcomes fall short. Delivery remains concentrated at a limited set of specialized centers requiring weeks of inpatient care.

For deeper context, see our Genomics analysis: "AI in Stem Cell Research: Top 10 Stem Cell Predictions and Trends in 2026".

For Investors

The expansion widens the addressable market but does not fix the ramp. First-quarter 2026 Casgevy sales of $42.9 million fell from $54.3 million in the prior quarter on infusion-timing variability. Vertex has forecast $500 million in combined 2026 revenue from Casgevy and its non-opioid painkiller Journavx, a 185% jump, according to BioSpace.

What Happens Next

Vertex said it has completed regulatory submissions in Saudi Arabia and the United Kingdom to expand Casgevy to children as young as five. Executives expect quarter-to-quarter revenue volatility to smooth out in 2027 as more patients move through the roughly year-long treatment journey. Watch adoption rates across the 75-plus authorized centers, Beam's BEAM-101 filing, and payer coverage terms for very young patients. Each younger-cohort clearance also extends the regulatory roadmap for the broader gene-editing field.

Additional coverage: Genomics Goes Enterprise: Azure–Nanopore, Bayer–Ginkgo Crop Pact and DNA Storage Pilots Announced

For deeper context, see our related analysis: "Beyond the Sequencer: What Genomics ROI Actually Looks Like in 2026".

Additional coverage: Why Genomics Solutions Need Agentic AI in Automation Workflows

Related: Bloomberg Intelligence Sees Genomics Reaching $90-120 Billion by 2030

FAQ

What did the FDA approve on July 1, 2026?
The FDA approved expanded use of Vertex and CRISPR Therapeutics' Casgevy for patients aged two and older with sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia, previously limited to ages 12 and up.

How many additional patients are now eligible?
Vertex said approximately 5,500 additional children in the U.S. are now eligible, accessible through more than 75 authorized treatment centers.

For deeper context, see our Data Centers analysis: "Equinix Gains as Data Center REITs Rally on Rate Bets and AI Demand".

How much does Casgevy cost and how is it paid for?
The one-time therapy is priced at $2.2 million. In the U.S., reimbursement runs partly through the CMS-led Cell and Gene Therapy Access Model, which negotiates outcomes-based terms with Vertex for state Medicaid programs.

How is Casgevy performing commercially?
Casgevy generated $42.9 million in the first quarter of 2026 and $116 million in full-year 2025. Vertex projects $500 million in combined 2026 revenue with its Journavx painkiller.

Who competes with Casgevy?
Beam Therapeutics is developing BEAM-101, a base-editing sickle cell therapy it plans to file by end-2026. Intellia and Editas are advancing in vivo CRISPR programs across other diseases.

Sources include company disclosures, regulatory filings, analyst reports, and industry briefings.

Related Coverage

• More Genomics Analysis
• Latest Technology News

Analysis based on company announcements, investor disclosures, regulatory filings, Reuters, Bloomberg, Financial Times, CNBC, SEC documentation, and publicly available market data as of publication.